EVH Evolent Health
- 23.280
- +0.390+1.70%
- 23.790
- +0.510+2.19%
Evolent Health News
Engaged Capital's Q1 Moves: Adds Envestnet, Trims Shake Shack, Others
Analysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (PRAX), Iovance Biotherapeutics (IOVA) and Evolent Health (EVH)
Truist Adjusts Evolent Health's Price Target to $28 From $34, Notes Near-Term Lack of Claims Visibility; Keeps Hold Rating
Truist Adjusts Evolent Health's Price Target to $28 From $34, Notes Near-Term Lack of Claims Visibility; Keeps Hold Rating.
Evolent Health, Inc. (NYSE:EVH) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Last week, you might have seen that Evolent Health, Inc. (NYSE:EVH) released its first-quarter result to the market. The early response was not positive, with shares down 9.7% to US$24.46 in the past
Evolent Health First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Evolent Health, Inc. (NYSE:EVH) Q1 2024 Earnings Call Transcript
Evolent Health Down Over 9%, on Pace for Largest Percent Decrease Since November 2022 -- Data Talk
Evolent Health Inc Class A (EVH) is currently at $24.44, down $2.52 or 9.35% --Would be lowest close since Nov. 2, 2023, when it closed at $24.01 --On pace for largest percent decrease since Nov. 3,
Evolent Health | 10-Q: Quarterly report
Evolent Health Inc (EVH) Surpasses Revenue Estimates Despite Net Loss in Q1 2024
Evolent Health Is Maintained at Market Outperform by JMP Securities
Evolent Health Is Maintained at Market Outperform by JMP Securities
Evolent Health Price Target Cut to $34.00/Share From $38.00 by JMP Securities
Evolent Health Price Target Cut to $34.00/Share From $38.00 by JMP Securities
J.P. Morgan Securities: Maintaining the Evolent Health (EVH.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $38.00 to $34.00.
J.P. Morgan Securities: Maintaining the Evolent Health (EVH.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $38.00 to $34.00.
JMP Securities Maintains Market Outperform on Evolent Health, Lowers Price Target to $34
JMP Securities analyst Constantine Davides maintains Evolent Health with a Market Outperform and lowers the price target from $38 to $34.
Evolent Health Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 38.41% JMP Securities $38 → $34 Maintains Market Outperform 04/22/2024 62.83% Citigroup → $40 I
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents
Evolent Down 9% Despite Quarterly Beats on Q2 EBITDA Guidance
Earnings Call Summary | Evolent Health(EVH.US) Q1 2024 Earnings Conference
The following is a summary of the Evolent Health, Inc. (EVH) Q1 2024 Earnings Call Transcript:Financial Performance:Evolent Health reported Q1 revenue of $639.7 million, a growth of 49.6% year-over-ye
UBS Trims Price Target on Evolent Health to $44 From $46, Keeps Buy Rating
Evolent Health (EVH) has an average rating of buy and price targets ranging from $34 to $63, according to analysts polled by Capital IQ. Price: 24.59, Change: -2.38, Percent Change: -8.81
Evolent Health Shares Are Trading Lower After the Company Reported Q1 Financial Results.
Evolent Health Shares Are Trading Lower After the Company Reported Q1 Financial Results.
Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say
Analysis
Price Target
No Data
